XOMA Corp. Stock
XOMA Corp. Stock
The price for the XOMA Corp. stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.850%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on XOMA Corp..
With a target price of 65 € there is potential for a 177.78% increase which would mean more than doubling the current price of 23.4 € for XOMA Corp..
So far the community has only identified positive things for XOMA Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of XOMA Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of XOMA Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| XOMA Corp. | -0.850% | 2.632% | 21.244% | 15.842% | 8.333% | 15.842% | -22.362% |
| Heron Therapeutics Inc. | -5.000% | -14.915% | -16.119% | -62.443% | -25.494% | -59.033% | -94.132% |
| Evolus Inc | 0.000% | -4.938% | 26.230% | -61.176% | -15.229% | -40.387% | -52.982% |
| Sangamo Therapeutics Inc. | -5.730% | 6.769% | 8.607% | -62.221% | -0.800% | -83.774% | -96.399% |
Comments
XOMA Royalty (NASDAQ:XOMA) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Royalty (NASDAQ:XOMA) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Royalty (NASDAQ:XOMA) was given a new $45.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for XOMA provided by MarketBeat